Cytoplasm

Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent

Retrieved on: 
Wednesday, December 15, 2021
Therapy, U.S. Securities and Exchange Commission, Technology, Patent, FDA, Company, ADS, 1836 U.S. Patent Office fire, HK, Growth, Private Securities Litigation Reform Act, Blood pressure, Istaroxime, Fast track (FDA), COVID-19, AHF, Heart, Sarcoplasmic reticulum, Annual report, USPTO, Form 10-K, CEO, Marketing, Patient, Cardiogenic shock, Security (finance), WINT, Heart rate, IP, Acute respiratory distress syndrome, GLOBE, Hypertension, Cytoplasm, Treatment, Pharmaceutical industry

The U.S. Patent, titled: Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF), covers longer infusion durations of istaroxime for improved outcomes in the treatment of acute heart failure.

Key Points: 
  • The U.S. Patent, titled: Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF), covers longer infusion durations of istaroxime for improved outcomes in the treatment of acute heart failure.
  • In particular, the patent refers to results in improvement in at least one echocardiographic indicator of diastolic function, which Windtree attributes to the SERCA2a mechanism of action of istaroxime and its metabolites.
  • Istaroxime is an investigational drug candidate being studied in acute heart failure and early cardiogenic shock.
  • Given the multiple development projects and programs we are advancing with istaroxime, we are pleased to have this patent contribute to the intellectual property protection of istaroxime, said Craig Fraser, CEO and President.

AcuraStem's Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALS

Retrieved on: 
Wednesday, December 15, 2021
Motor neuron, Drug discovery, Shi, DOD, Alzheimer's Drug Discovery Foundation, Department of Defense Serum Repository, ALS, Nature Medicine, Unitary state, Alzheimer's disease, Translational medicine, National Institute of Neurological Disorders and Stroke, National, Stroke, Survival, Motor neuron disease, Mace Head Atmospheric Research Station, Safety, Patient, Machine learning, PIKFYVE, Therapy, Pathology, Drug development, Department, Government, Neurodegeneration, Amyotrophic lateral sclerosis, Neuron, Cytoplasm, International Symposium on Endovascular Therapy, Human, Barrow Neurological Institute, Pharmaceutical industry, Dentistry, Medical device, Nature

These improvements were driven by a rescue of motor neuron degeneration and TDP-43 pathology in the treated mice.

Key Points: 
  • These improvements were driven by a rescue of motor neuron degeneration and TDP-43 pathology in the treated mice.
  • Importantly, the data demonstrates that AS-202 is a potent PIKFYVE suppressor with no significant off-target effects in human cells, and was well-tolerated in rodent models at high doses.
  • "The current preclinical data show that AS-202 could translate into an exciting new clinical approach to treating ALS."
  • AcuraStem's iNeuroRx technology platform, which combines patient-derived disease models and human genetic data at scale, has validated Dr. Ichida's discovery in many ALS patient-derived models including both sporadic and multiple, genetically defined forms of ALS.

DGAP-News: Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Retrieved on: 
Thursday, December 2, 2021
Patient, Gesellschaft mit beschränkter Haftung, CEO, Orthohantavirus, Safety, CSO, Cell, Pharming, CMC, KU Leuven, Company, Viral load, MEK, Severe acute respiratory syndrome coronavirus 2, Gene expression, The Nomad Soul, Cytoplasm, COVID-19, History, Orthornavirae, Patent, RNP, RNA, Macrophage inflammatory protein, RSV, III, Therapy, Degenerative disease, Medicinal chemistry, Pharmaceutical industry, Vaccine, zapnometinib's mode of action with dual benefit, Atriva Therapeutics GmbH, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL BENEFIT, ATRIVA THERAPEUTICS GMBH

Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva's advisory board, bringing vast experience in late-stage pharmaceutical development

Key Points: 
  • Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva's advisory board, bringing vast experience in late-stage pharmaceutical development
    Frans van Dalen, Pharm D., representative of Atriva's lead investor Meneldor, continues support for Atriva on the scientific board
    Tbingen and Frankfurt, Germany, December 02, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes in its advisory board and its scientific board: Effective December 1, Piet Wigerinck, Ph.D., former Chief Scientific Officer (CSO) of the Belgian biotech company Galapagos, will join Atriva's advisory board on behalf of lead investor Meneldor.
  • D., founding partner and representative of Meneldor in Atriva's advisory board until now, will take a seat on the scientific board to continue his support for Atriva.
  • Paul Lelieveld, Ir., founding partner of Meneldor, said: "We warmly welcome Piet as a representative of Meneldor on the advisory board of Atriva.
  • Dr. Piet Wigerinck said: "I am very pleased to join the Atriva Therapeutics board at an exciting moment in its history.

Yokogawa Develops Single Cellome System SS2000 for Subcellular Sampling

Retrieved on: 
Wednesday, December 1, 2021
Science, Stem Cells, Research, Pharmaceutical, Hardware, Health, Medical Devices, Technology, Safety, Cell, Technology, Mass spectrometry, Population, Yokogawa Electric, Health, Precision medicine, Solution, Cytoplasm, Single-cell analysis, 3D, View, Research, Communication, Collection, Organization, Regenerative medicine, Organelle, Food, Name, Multimedia, Drug discovery, Single, Yaskawa Electric Corporation, Microscope, Vaccine

Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed the Single Cellome System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components.

Key Points: 
  • Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed the Single Cellome System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components.
  • In recent years, with improved analytical technology, it has become possible to analyze not only single cells but also specific molecules within them.
  • Utilizing Yokogawas core imaging technologies that enable the real-time analysis of minute phenomena in live cells, the Single Cellome System SS2000 incorporates new technologies that automatically and accurately control sampling operations in order to support the performance of cutting-edge life science research.
  • Hiroshi Nakao, a Yokogawa Electric vice president and head of the Life Business Headquarters, comments, "The newly developed Single Cellome System SS2000 is a solution that will play a key role in future cell research.

DGAP-News: DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Retrieved on: 
Tuesday, November 30, 2021
Research, Cervical cancer, HPV, B cell, Peptide, Protein, Cell, Technology, Forward-looking statement, Company, News, Cancer, Antigen, DGAP, Breast, Catastrophic illness, Therapy, Breast cancer, Cytoplasm, COVID-19, Vaccine, CSE, Vaccination, Mouse, Immunoglobulin G, Survival rate, E7, Melanoma, Cytosol, GLP, Endosome, ADC, Antibody, FDA, IGAS, PH, DC, Infection, Organelle, Engineering, Trastuzumab emtansine, The Company, E6, Control, Enzyme, Colon, Antibody-drug conjugate, IP, Security (finance)

Vancouver, BC, Canada, November 30th 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform.

Key Points: 
  • Vancouver, BC, Canada, November 30th 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform.
  • The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological interest to target cells and increases the intracellular accumulation to these targeted cells.
  • Another infectious disease vaccine in development at Defence Therapeutics is AccuVAC-PT009 targeting HPV.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.

Experimental Compound Counters Diabetic Complications

Retrieved on: 
Wednesday, November 24, 2021
Tissue, Patient, DIAPH1, Defense, Swelling, Heart, Cell, Diabetes, Science Translational Medicine, Bacteria, RAGE, MD, End organ damage, Diet, Virus, Drug discovery, Fed, State University of New York Upstate Medical University, Inflammation, Population health, United States Department of Defense, Department, Male, Cytoplasm, DAMPS, Cell death, Pain, Mouse, Muscle tissue, Columbia University Irving Medical Center, Metabolism, Kidney, Kidney bean, Gaps, DNA, Female, Research, Risk, State university system, Columbia University, NYU, Pathology, DAMP, Environmental medicine, Princeton University Department of Chemistry, Immune system, New York University Grossman School of Medicine, Division, Infection, Meal, NYU Langone Health, Plastic surgery, United States Public Health Service, Pharmaceutical industry, Vaccine

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- An experimental compound reduced complications of type 1 and type 2 diabetes in mice not by lowering blood sugar but by countering its consequences: cell death, inflammation, and organ damage.

Key Points: 
  • NEW YORK, Nov. 24, 2021 /PRNewswire/ -- An experimental compound reduced complications of type 1 and type 2 diabetes in mice not by lowering blood sugar but by countering its consequences: cell death, inflammation, and organ damage.
  • The results revolve around the body's immune system, which recognizes and destroys invading bacteria and viruses.
  • Experiments in human cells and mouse models found that the lead study compound, RAGE229, significantly reduced short- and long-term complications of diabetes.
  • The team next incorporated the RAGE229 molecule into mouse chow because dietary intake could better measure its ability to reverse long-term complications like diabetic wounds.

Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation

Retrieved on: 
Monday, November 22, 2021
Patient, Heart, Blood pressure, Heart failure, Security (finance), CEO, Safety, Data analysis, Heart rate, AHF, Agency for Healthcare Research and Quality, Technology, Infarction, ADS, Brain, Hypertension, Private Securities Litigation Reform Act, Company, HK, Cardiology, SCAI, Cardiogenic shock, SBP, Agency, AHRQ, Blood, Kidney, U.S. Securities and Exchange Commission, Cytoplasm, COVID-19, Annual report, Istaroxime, Arrhythmia, Research, Risk, GLOBE, WINT, Oxygen, Marketing, FDA, Mortality, Form 10-K, Sarcoplasmic reticulum, Therapy, Length of stay, Acute respiratory distress syndrome, Disease, Growth, Pharmaceutical industry, Health insurance

Cardiogenic shock is a serious condition that occurs when the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs.

Key Points: 
  • Cardiogenic shock is a serious condition that occurs when the heart cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs.
  • U.S. hospital claims data reveals that inpatient mortality for cardiogenic shock patients was 30% in 2020.2 To help explain the relative severity of cardiogenic shock, the acute myocardial infarction (e.g.
  • Additionally, U.S. hospital claims data was assessed to determine length of stay in the hospital for cardiogenic shock patients.
  • The istaroxime phase 2 study in early cardiogenic shock is an international, randomized, double blind, placebo- controlled study.

Vesigen Therapeutics Presents at 3rd Exosome-Based Therapeutic Development Summit: Expanding the Therapeutic Boundaries of Exosomes

Retrieved on: 
Tuesday, November 16, 2021
Biotechnology, Health, Genetics, Science, Research, Harvard University, Horizontal Environmental Genetic Alteration Agents, Therapy, Reunion, Intrinsic termination, Regenerative medicine, Autoimmunity, Tissue, RNA transfection, Harvard T.H. Chan School of Public Health, Doctor of Philosophy, HIV, Technology, Exosome, RNA, COVID-19, ARMM Regional Legislative Assembly, Protein, Biotechnology, Virus, Cytoplasm, Enzyme, Summit, Public health, Seminal vesicles, Cell, Physiology, Patient, Genetics, Pharmaceutical industry, Vaccine, Vesigen Therapeutics, ARMMs, VESIGEN THERAPEUTICS, ARMMS

These results illustrate the ability of Vesigens proprietary platform to produce ARMMs in a scalable process and effectively deliver functional payloads.

Key Points: 
  • These results illustrate the ability of Vesigens proprietary platform to produce ARMMs in a scalable process and effectively deliver functional payloads.
  • Using ARMMs as drug delivery vehicles overcomes hurdles faced by other viral and non-viral delivery platforms, said Joseph Nabhan, PhD, Chief Scientific Officer at Vesigen Therapeutics.
  • Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology.
  • Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.

DGAP-News: Atriva Therapeutics' lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2

Retrieved on: 
Tuesday, November 9, 2021
Safety, MEK, Manuscript, Therapy, III, CRO, Macrophage inflammatory protein, Clinical trial, Gesellschaft mit beschränkter Haftung, RNA, Drug nomenclature, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, CSO, RSV, COVID-19, Orthohantavirus, Gene expression, Vaccine, Company, Antibody, Laboratory, Virus, Cytoplasm, RNP, Patent, Cell, Patient, Orthornavirae, Viral load, Transfusion-related acute lung injury, Pharmaceutical industry, zapnometinib's mode of action with dual benefit, Atriva Therapeutics GmbH, Viroclinics-DDL, ZAPNOMETINIB'S MODE OF ACTION WITH DUAL BENEFIT, ATRIVA THERAPEUTICS GMBH, VIROCLINICS-DDL

Tbingen and Frankfurt, Germany, November 09, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced new results on the efficacy of Atriva's lead candidate zapnometinib against coronaviruses.

Key Points: 
  • Tbingen and Frankfurt, Germany, November 09, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced new results on the efficacy of Atriva's lead candidate zapnometinib against coronaviruses.
  • The preclinical study investigated the antiviral efficacy of zapnometinib against SARS-CoV-2 compared to drug-free controls in a well-established preclinical infection model based on Syrian hamsters.
  • The cell culture-based assays demonstrated that zapnometinib successfully inhibited viral replication by more than 90 % in all viruses tested.
  • The Atriva lead product zapnometinib (pINN, currently known as ATR-002) is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses.

Ventus Therapeutics to Present Data on Novel cGAS Small Molecule Inhibitors in the Modulation of Auto-Inflammation

Retrieved on: 
Wednesday, November 3, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Infection, UVB, Neurology, National Center for Advancing Translational Sciences, Biotechnology, Acute cutaneous lupus erythematosus, LinkedIn, Nucleic acid metabolism, Inflammation, Industry, Neurodegeneration, Drug development, Human, Dermatomyositis, Patient, Lupus, Cytokine, Pain scale, NLRP3, Chemokine, Ultraviolet, Protein, Mitochondrial disease, Cytoplasm, Resolve, COVID-19, Computational chemistry, Lists of diseases, American College, Bureau of Oceans and International Environmental and Scientific Affairs, Therapy, Cyclic GMP-AMP synthase, Doctor of Philosophy, Mouse, TREX1, DNA, Fine chemical, Pharmaceutical industry, Vaccine

These presentations will highlight results that describe how Ventus proprietary technology and enablement could drive the design of chemically distinct cGAS-targeted small molecule therapeutics capable of addressing a wide range of indications.

Key Points: 
  • These presentations will highlight results that describe how Ventus proprietary technology and enablement could drive the design of chemically distinct cGAS-targeted small molecule therapeutics capable of addressing a wide range of indications.
  • cGAS has been a challenging target for small molecule drug discovery and to our knowledge there is no cGAS inhibitor in clinical development, said Michael Crackower, PhD, Chief Scientific Officer of Ventus.
  • cGAS is a sensor of double-stranded DNA in the cytoplasm; cytoplasmic DNA can be indicative of infection, mitochondrial disease or nuclear leakage.
  • Ventus Therapeutics is a biopharmaceutical company utilizing cutting-edge computational tools to design small molecule therapeutics across multiple therapeutic areas, including immunology, inflammation and neurology.